CN104040342A - 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途 - Google Patents

抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途 Download PDF

Info

Publication number
CN104040342A
CN104040342A CN201280065165.6A CN201280065165A CN104040342A CN 104040342 A CN104040342 A CN 104040342A CN 201280065165 A CN201280065165 A CN 201280065165A CN 104040342 A CN104040342 A CN 104040342A
Authority
CN
China
Prior art keywords
synuclein
antibody
nucleoprotein
level
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280065165.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·魏霍芬
T·恩格贝尔
J·格林姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio International Mandatory Drug Abuse Association International Neuroscience Corp
Original Assignee
Bio International Mandatory Drug Abuse Association International Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio International Mandatory Drug Abuse Association International Neuroscience Corp filed Critical Bio International Mandatory Drug Abuse Association International Neuroscience Corp
Priority to CN201710252366.1A priority Critical patent/CN107091931A/zh
Publication of CN104040342A publication Critical patent/CN104040342A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201280065165.6A 2011-11-02 2012-10-29 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途 Pending CN104040342A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710252366.1A CN107091931A (zh) 2011-11-02 2012-10-29 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161554924P 2011-11-02 2011-11-02
US61/554,924 2011-11-02
PCT/US2012/062430 WO2013066818A1 (en) 2011-11-02 2012-10-29 USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710252366.1A Division CN107091931A (zh) 2011-11-02 2012-10-29 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途

Publications (1)

Publication Number Publication Date
CN104040342A true CN104040342A (zh) 2014-09-10

Family

ID=48192661

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280065165.6A Pending CN104040342A (zh) 2011-11-02 2012-10-29 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途
CN201710252366.1A Pending CN107091931A (zh) 2011-11-02 2012-10-29 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710252366.1A Pending CN107091931A (zh) 2011-11-02 2012-10-29 抗α‑共核蛋白抗体诊断脑中的α‑共核蛋白的升高水平的用途

Country Status (13)

Country Link
US (3) US20140295465A1 (enExample)
EP (1) EP2773957B1 (enExample)
JP (1) JP6263473B2 (enExample)
KR (1) KR102036938B1 (enExample)
CN (2) CN104040342A (enExample)
AU (1) AU2012332814B2 (enExample)
BR (1) BR112014010664A2 (enExample)
CA (1) CA2854131C (enExample)
EA (1) EA034213B1 (enExample)
IL (1) IL232373B (enExample)
MX (1) MX356797B (enExample)
WO (1) WO2013066818A1 (enExample)
ZA (1) ZA201403879B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2370466E (pt) 2008-12-19 2015-09-21 Univ Zuerich Autoanticorpos humanos anti-alfa-sinucleína
AU2012272790B2 (en) 2011-06-23 2016-10-06 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
JP6273338B1 (ja) * 2016-12-05 2018-01-31 磁量生技股▲ふん▼有限公司 パーキンソン病からパーキンソン病認知症を特定する方法
CN110494445B (zh) 2017-01-06 2023-10-20 Abl生物公司 抗α-SYN抗体及其用途
AU2018206279B2 (en) * 2017-01-06 2020-09-03 Abl Bio Inc. Anti-alpha-syn antibody and use thereof
US11142570B2 (en) 2017-02-17 2021-10-12 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CN116731173A (zh) 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
EP3629021A1 (en) * 2018-09-26 2020-04-01 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
AU3117799A (en) * 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
EP1299411A4 (en) * 2000-07-07 2006-02-15 Panacea Pharm Llc METHOD FOR PREVENTING INJURY OF NEURAL TISSUE AND TREATING ALPHA SYNUCLEINE-RELATED DISEASES
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
US20080300204A1 (en) * 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
PL2099826T3 (pl) 2007-01-05 2014-04-30 Univ Zuerich Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
LT2282758T (lt) * 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069603A1 (en) * 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies

Also Published As

Publication number Publication date
KR102036938B1 (ko) 2019-10-25
MX356797B (es) 2018-06-14
EP2773957B1 (en) 2017-11-29
CN107091931A (zh) 2017-08-25
EA034213B1 (ru) 2020-01-17
IL232373A0 (en) 2014-06-30
WO2013066818A1 (en) 2013-05-10
IL232373B (en) 2018-08-30
HK1201585A1 (en) 2015-09-04
BR112014010664A2 (pt) 2017-04-25
JP2014533357A (ja) 2014-12-11
KR20140095074A (ko) 2014-07-31
EP2773957A1 (en) 2014-09-10
EA201490883A1 (ru) 2014-10-30
ZA201403879B (en) 2018-11-28
NZ625217A (en) 2016-07-29
MX2014005378A (es) 2015-01-19
CA2854131A1 (en) 2013-05-10
AU2012332814B2 (en) 2017-12-14
AU2012332814A1 (en) 2014-06-12
US20190094245A1 (en) 2019-03-28
EP2773957A4 (en) 2015-06-24
CA2854131C (en) 2020-07-07
JP6263473B2 (ja) 2018-01-31
US20140295465A1 (en) 2014-10-02
US20180011112A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
CN104040342A (zh) 抗α-共核蛋白抗体诊断脑中的α-共核蛋白的升高水平的用途
US12454575B2 (en) Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies
US9849165B2 (en) Oligomer-specific amyloid beta epitope and antibodies
AU2012262007A1 (en) Fc receptor binding proteins
JP2018511609A (ja) 発作性夜間血色素尿症（ｐｎｈ）患者の亜集団の同定および処置
KR20250060282A (ko) 조혈모세포 이식-연관 혈전성 미세혈관병증(hsct-tma)을 치료하기 위한 항-c5 항체의 보충 투약 및 투여
HK1201585B (en) Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain
NZ625217B2 (en) Use of an anti-?-synuclein antibody to diagnose an elevated level of ?-synuclein in the brain
NZ715057B2 (en) Fc Receptor Binding Proteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Swiss Shi Lilun

Applicant after: Biological neuroscience international company

Address before: Swiss Shi Lilun

Applicant before: International neuroscience company of association gives up taking addictive drugs by force in the biological world

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: BIOGEN IDEC INTERNALTIONAL NEUROSCIENCE GMBH TO: BIOGEN INTERNALTIONAL NEUROSCIENCE GMBH

Free format text: CORRECT: ADDRESS; FROM:

RJ01 Rejection of invention patent application after publication

Application publication date: 20140910

RJ01 Rejection of invention patent application after publication